Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(19):1433; doi:10.1093/jnci/93.19.1433
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 19, 1433, October 3, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Selective Estrogen Receptor Modulation

Jordan et al. (p. 1449) reviewed the status of knowledge of selective estrogen receptor modulation. They pointed out that the laboratory studies so far have resulted in the development of two selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene, for clinical application in healthy women. These SERMs have antiestrogenic effects in the breast tissue but have estrogen-like activity in the bones and in reducing blood cholesterol levels. SERMs have different estrogen-like effects in the uterus. Tamoxifen is specifically used to reduce the incidence of breast cancer in high-risk premenopausal and postmenopausal women. In contrast, raloxifene is . . . [Full Text of this Article]

DNA Repair Mechanisms and Resistance to Nitrogen Mustards

Familial Multiple Myeloma

Lung Cancer Modifier Genes

Methylation in Coding Regions

Prostasin, a Potential Serum Marker for Ovarian Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?